We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$6.32M 1.26%
699,440
+107,317
+18% +$719K
GOSS icon
27
CALL
Gossamer Bio
GOSS
$101M
$6.31M 1.26%
526,600
+192,100
+57% +$2.38M
KZR
28
DELISTED
Kezar Life Sciences
KZR
$6.27M 1.25%
72,859
-67,953
-48% -$6.6M
SAGE
29
DELISTED
Sage Therapeutics
SAGE
$6.18M 1.23%
+157,805
New +$6.1M
TCDA
30
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.05M 1.21%
+577,600
New +$6.32M
ALT icon
31
Altimmune
ALT
$568M
$6.03M 1.2%
472,054
-425,305
-47% -$6.28M
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.1B
$5.79M 1.15%
160,486
-78,955
-33% -$2.84M
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
$5.33M 1.06%
904,119
+204,119
+29% +$758K
ACAD icon
34
Acadia Pharmaceuticals
ACAD
$4.51B
$5.32M 1.06%
+325,000
New +$5.26M
HZNP
35
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.27M 1.05%
85,100
-14,900
-15% -$1.04M
CERE
36
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$5.03M 1%
+178,100
New +$5.3M
STOK icon
37
PUT
Stoke Therapeutics
STOK
$1.84B
$4.73M 0.94%
+368,700
New +$5.88M
TCON
38
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$4.62M 0.92%
138,277
-1,166
-0.8% -$44.5K
HZNP
39
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.59M 0.92%
74,219
-85,897
-54% -$6M
IMVT icon
40
Immunovant
IMVT
$7.93B
$4.53M 0.9%
+811,700
New +$3.97M
ARVN icon
41
CALL
Arvinas
ARVN
$530M
$4.45M 0.89%
+100,000
New +$4.85M
PRTA icon
42
CALL
Prothena Corp
PRTA
$448M
$4.05M 0.81%
+66,800
New +$2.11M
ARDX icon
43
Ardelyx
ARDX
$1.24B
$3.78M 0.75%
3,178,825
+1,498,273
+89% +$1.43M
ABOS icon
44
Acumen Pharmaceuticals
ABOS
$152M
$3.51M 0.7%
+350,000
New +$2.01M
PNT
45
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.48M 0.69%
+450,406
New +$3.82M
RETA
46
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.47M 0.69%
138,100
-23,900
-15% -$662K
JBIO
47
Jade Biosciences
JBIO
$1.18B
$3.32M 0.66%
+5,714
New +$3.81M
ARKG icon
48
ARK Genomic Revolution ETF
ARKG
$1.53B
$3.17M 0.63%
+96,462
New +$3.54M
SCPH
49
DELISTED
scPharmaceuticals
SCPH
$3.13M 0.62%
479,383
-404,625
-46% -$2.16M
MIST icon
50
PUT
Milestone Pharmaceuticals
MIST
$129M
$3.11M 0.62%
+338,000
New +$2.56M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.